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Abstract. In a search for novel vitamin D derivatives of 
potential therapeutic value, structurally simple but 
synthetically challenging A-ring epimers of the 19-nor-
Calcitriol [19-nor-1α,25-(OH)2-D3] at C1 and C3 were 
efficiently synthesized. Both analogues (1-epi- and 3-epi-
19-nor-Calcitriol) were obtained through a convergent 
synthesis starting from cis,cis-1,3,5-cyclohexanetriol and 
the protected 25-hydroxy Grundmann´s ketone. After Julia-
Kocienski coupling of the corresponding C,D-ring/side 
chain sulfone fragment with the A-ring ketone moiety, both 
vitamin D analogues were isolated. The critical point was 
how to determine the structural configuration of both 
diastereoisomers since similar 1H NMR spectra were 
observed. For that, a biocatalytic approach was crucial in 
the synthesis of orthogonally protected derivatives. NMR 
spectroscopy allows the unambiguous identification of 
these compounds and as a result the structural elucidation 
of the desired vitamin D diastereomeric analogues. Affinity 
studies demonstrated that these 1,25-19-nor analogues have 
a very low affinity for the vitamin D receptor compared 
with 1α,25-dihydroxyvitamin D3 or 1α,25-dihydroxy-19-
nor-vitamin D3. In addition, these analogues have a lower 
binding affinity for the human vitamin D binding protein 
than the natural hormone. In vitro cell culture studies 
revealed that synthesized analogues were less active than 
1α,25-dihydroxyvitamin D3 in inhibiting cell proliferation. 
Keywords: Enzymatic desymmetrization; Vitamin D; 19-
nor analogues; A-Ring modified analogues; Calcitriol 
Introduction 
Due to its huge biological importance, 1α,25-(OH)2-
D3 (2, Calcitriol, Figure 1), the hormonally active 
form of vitamin D3 (1), was considered as a candidate 
for therapeutic usage. However, side effects like 
hypercalcemia and hypercalciuria hobble its 
pharmaceutical interest.[1]  
 
Figure 1. Vitamin D and 19-nor-analogues. 
For this reason, research related to vitamin D and 
especially focused at Calcitriol, has provided 
synthetic routes and biological activities for over 
3,000 new analogues. Nowadays, the emphasis is on 
obtaining molecules with enhanced molecular activity 
as well as reduced calcemic effects.[2] Simple 
modifications on the structure of the natural hormone 
led to interesting analogues. There are several 
examples where the chirality importance is reflected 
because of stereoisomers of the same analogue 
having remarkably different biological profiles. For 
example, the stereochemistry of C1 and C3 has a 
strong impact on binding to the vitamin D receptor 
(VDR) and also to the vitamin D binding protein 
(DBP). Inversion of the natural orientation of the 3b-
hydroxyl and 1α-hydroxyl resulted in a 4- to 90-fold 
reduction in VDR binding. However, inversion of the 
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1α-hydroxyl to the 1β-orientation results in a 65.7-
fold increase in DBP binding with respect to 1α,25-
(OH)2-D3, illustrating that the optimal ligand for DBP 
is 25-OH-D3. Intriguingly, 1β,25-(OH)2-D3 was found 
to be a specific inhibitor of the nongenomic responses 
of 1α,25-(OH)2-D3 such as transcaltachia and Ca2+ 
uptake, making it the first analogue that displays 
antagonist properties at the receptor level.[3] 
It is noteworthy that the removal of the 19-
exomethylene function is beneficial in itself. Thus, 
1α,25-dihydroxy-19-nor-vitamin D3 (3) shows minor 
calcemic effects while retaining good cell-
differentiating properties.[4] In an attempt to carry out 
the preparation of the corresponding C1 and C3 
diastereoisomers of 1α,25-(OH)2-14-epi-19-nor-D3 
analogues, Wu et al.[5] described the preparation of 1-
epi and 3-epi derivatives of TX522 (4−6, Figure 1) 
through a convergent process whose key step 
involves the coupling between an aldehyde of A-ring 
derivative and an allyl bromide CD-ring fragment. 
The main drawback of this route is the low selectivity 
obtained in the solvolysis of the coupling reaction 
product (cyclovitamin intermediate). It proceeds 
through an intermediate with two rotamers in 
equilibrium around the 5,6-bond. This disadvantage 
along with the challenging identification of both 
isomers has been a barrier to expand the methodology 
to the synthesis of 1-epi or 3-epi derivatives of 1α,25-
(OH)2-19-nor-D3. 
With this goal in mind, here we report a practical 
approach for the preparation of the synthetically 
elusive epimers C3 and C1 of 1α,25-(OH)2-19-nor-D3 
(7 and 8, respectively, Figure 2). 
 
Figure 2. C1 and C3 epimers of 1α,25-(OH)2-19-nor-D3. 
Results and Discussion 
Chemistry 
The convergent construction of the vitamin D 
skeleton is based on an approach previously reported 
by Kittaka.[6] The synthesis of compounds 7 and 8 
was envisaged using a Julia-Kociensky olefination to 
construct the diene unit between the A-ring and the 
CD-ring/side chain fragment, which was previously 
reported starting from Grundmann´s ketone.[7] The 
synthesis of A-ring synthon 11 was developed as 
shows in Scheme 1. Treatment of cis,cis-1,3,5-
cyclohexanetriol (9) with Et3N, and tert-
butyldimethylsilyl chloride (TBDMSCl) at –20 ºC led 
to the corresponding di-silyl protected derivative 10, 
which was next treated with Dess-Martin periodinane 
reagent to achieve the ketone 11. 
 
Scheme 1. Preparation of symmetric A-ring synthon 11. 
Reaction conditions: (a) TBDMSCl, Et3N, THF, −20 ºC, 
2 h and then 16 h at r.t. (43%); (b) Dess-Martin reagent, 
CH2Cl2, r.t., 30 min (97%). 
Convergent coupling reaction between 11 and the 
lithium enolate of sulfone 12 (Scheme 2) took place 
with 51% yield, giving an equimolecular 
diastereomeric mixture, which was hardly separated 
by HPLC. For this reason, the mixture was treated 
with tetrabutylammonium fluoride (TBAF), which 
resulted in silyl ether deprotection, affording the 
isomers 13 and 14. These compounds were easily 
separated by semipreparative HPLC in an equimolar 
ratio (see Figure S1, Supporting Information). 
 
Scheme 2. Synthesis of 1-epi and 3-epi 19-nor-vitamin 
D3 analogues. Reaction conditions: (a) LHMDS, THF, −78 
ºC to −50 ºC, 7 h (51%); (b) TBAF, THF, r.t., 2 h (85%); 
(c) EtOH sat HCl, r.t., 30 min (88% for 7 and 91% for 8). 
Structure determination from conventional 
techniques was challenging due to the structural 
similarity of both isomers. Accordingly, an extensive 
NMR study was performed using a high resolution 
NMR spectrometer. Despite the fact of using a 600 
MHz apparatus, we were not able to distinguish the 
diastereomers 13 and 14 by NMR methods (see 
Figure S2, Supporting Information). 
To deduce unequivocally the correct 
stereochemistry of both analogues, our efforts were 
focused on the design of a new route for the synthesis 
of an A-ring synthon in which orthogonal protection 
of hydroxyl groups would be the key to solve the 
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problem of the structural determination (Scheme 3). 
For this purpose, we take into account the pioneering 
work of Wirz and co-workers,[8] who carried out the 
acetylation of corresponding mono-TBDMS-
protected derivative of 9 catalyzed by QLM lipase to 
afford the asymmetrically monoacylated compound 
in quantitative yield and >99% ee. In our case, to 
facilitate the analysis of the enzymatic reaction by 
HPLC, we used as silyl ether the TBDPS (UV 
visible) instead the TBDMS group. 
 
Scheme 3. Preparation of orthogonally protected A-ring 
synthon 19. Reaction conditions: (a) TBDPSCl, Et3N, NaH, 
THF, 45 ºC, 48 h (85%); (b) Lipase, vinyl acetate, solvent, 
30 ºC; (c) TBDMSCl, Imidazole, CH2Cl2, r.t., 3 h (94%); 
(d) MeONa, MeOH, r.t., 4 h (95%); (e) Dess-Martin 
reagent, CH2Cl2, r.t., 1 h (97%). 
Thus, triol 9 was mono-TBDPS-protected by 
treatment with tert-butyldiphenylsilyl chloride 
(TBDPSCl), Et3N, and NaH in THF at 40 ºC to afford 
the diol 15 in 85% yield.[9] At this point, two different 
easily available lipases were tested for the 
asymmetric acetylation of meso-diol 15 in vinyl 
acetate: Candida antarctica lipase type B (CAL-B, 
Novozyme 435) and Pseudomonas cepacia lipase 
(PSL-IM). The choice of these enzymes was based on 
the excellent results that they showed in enzymatic 
resolution of secondary alcohols via enantioselective 
acylation or hydrolysis of their esters.[10] 
Table 1. Lipase catalyzed acylation of 15.a) 
 Enzymeb) Solvent t 
(h) 
15 
(%)b) 
16 
(%)b) 
16 ee 
(%)b) 
20 
(%)b) 
1 - THF 12 >99 - - - 
2 - Toluene 12 >99 - - - 
3 - TBME 12 >99 - - - 
4 CAL-B THF 12 - 92 >99 8 
5 CAL-B Toluene 12 9 85 98 6 
6 CAL-B TBME 10 - 90 97 10 
7 PSL-IM THF 12 74 24 85 2 
8 PSL-IM Toluene 4 - >99 >99 - 
9 PSL-IM TBME 4 - >99 >99 - 
a) Ratio 15:enzyme (1:0.5, p/p), with vinyl acetate at 30 ºC. 
b) Determined by chiral HPLC. 
Enzymatic catalysis in non-aqueous media 
significantly extends the conventional aqueous-based 
biocatalysis.[11] The effect of three different organic 
solvents [THF, tert-butylmethyl ether (TBME), and 
toluene] on the process was evaluated. The reactions 
were carried out at 30 ºC using 5 equiv. of vinyl 
acetate. Candida antarctica lipase B (CAL-B), 
showed very high enantioselectivity in all solvents 
(entries 4−6, Table 1) but different regioselectivities: 
total conversion was achieved with THF and TBME, 
after 12 and 10 h, respectively, but the diacetylated 
product 20 was also obtained. Using toluene as 
solvent, the reaction was slower and after 12 h 
starting material was recovered. 
On the other hand, when the acylation process of 
15 was examined with Pseudomonas cepacia lipase 
as catalyst and THF as solvent, lower reaction rate 
and enantioselectivity were observed (entry 7, Table 
1). On the contrary, excellent results were obtained 
using toluene and TBME (entries 8−9, Table 1). Thus, 
99% conversion was achieved after 4 h of reaction 
and enantiopure (−)-16 was obtained (see Figure S3, 
Supporting Information). 
 
Scheme 4. Synthesis of enantiomerically pure diacetate 
22. Reaction conditions: (a) Ph3P, DIAD, AcOH, THF, r.t., 
4 h (72%); (b) TBAF, THF, r.t., 3 h (79%). 
Both enzymes showed the same stereochemical 
preference. For the assignment of the absolute 
configurations of 16, a sequence of chemical 
transformations were carried out to convert the 
optically pure compound (−)-16 into the previously 
described[8] (+)-1,3-diacetoxy-5-hydroxycyclohexane 
22 (Scheme 4). Inversion of the free hydroxyl group 
in 16 under Mitsunobu conditions furnished 21. 
Subsequent removal of the silyl ether with TBAF 
afforded the corresponding diacylated diol (+)-22. 
The comparison of the specific rotation of this 
compound to that described in the literature led us to 
determine the (1R,3S,5S)-absolute configuration for 
the product (−)-16 obtained from the enzymatic 
acylation.[8] 
The synthesis of the A-ring synthon was completed 
with three additional steps (Scheme 3). The treatment 
of 16 with TBDMSCl and imidazole led us to achieve 
the compound 17, which bears orthogonal protection 
for its three hydroxyl groups. Sequentially, the 
removal of acetyl group in basic conditions afforded 
the alcohol 18, which was treated with Dess-Martin 
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periodinane reagent to give the final A-ring synthon 
19. The absolute configuration was maintained in all 
steps, as it was verified by quiral HPLC analysis of 
compound 18 (see Figure S4, Supporting 
Information). 
 
Scheme 5. Synthesis of 19-nor-vitamin D analogues. 
Reaction conditions: (a) LHMDS, THF, −78 ºC to −50 ºC, 
7 h (63%); (b) Bi(OTf)3, CH2Cl2, 0 ºC, 2 h (75%); (c) 
EtOH sat HCl, r.t., 30 min (89%). 
A-Ring modified 19-nor-vitamin D3 analogues 
were synthesized through the Julia-modified coupling 
reaction as illustrated in Scheme 5. Reaction of 
ketone 19 with the lithium enolate of sulfone 12 gave 
a mixture of diastereomers 23 and 24. The separation 
of 23 and 24 by semipreparative HPLC was not 
possible due to their low polarity, which was later 
modulated through hydroxyl group deprotection. 
On the other hand, the hydroxyl groups must be 
differentiated from each other for stereochemical 
determination. Therefore, different conditions were 
tested to carry out the selective deprotection of 
TBDMS vs TBDPS group. The best result was 
achieved using a Lewis acid, Bi(OTf)3, in an organic 
solvent. The removal of the ethoxymethyl protecting 
group in the side chain took place simultaneously, 
providing a 1.37:1 diastereomeric mixture of 
analogues 25 and 26 that were successfully separated 
by HPLC. At this stage, we called diastereomer 
compounds A and B according to the rate of elution 
in the HPLC chromatogram (see Figure S5, 
Supporting Information). The identification of the 
synthesized analogues was performed by NMR. The 
protons at C6 and C7 in the 1H NMR spectrum, and 
also the signals corresponding to the carbons C14 and 
C17 could be identified by monodimensional DEPT-
135, DEPT-90 and bidimensional 13C-1H HMBC 
analysis (see pp S55-S60, Supporting Information). 
At this point, the 1D NMR selective NOE 
experiments were the key to undoubtedly complete 
the structure elucidation for both isomers. In the case 
of compound A, the selective irradiation of H7 
allowed us to identify H10 (Figure 3). This signal 
was also showed in the 1D NMR selective NOE 
experiment on the multiplet at 4.08 ppm. In this 
second experiment we could also observe NOE 
signals with the ortho aromatic protons of the TBDPS 
group. This proved that the signal at 4.08 ppm 
belonged to the proton adjacent to OTBDPS and that 
this silyl ether was in the position C1. Moreover, this 
aromatic signal and H7 were close enough to exhibit 
a NOE enhancement. These data led us to identify the 
isomer A with the structure of 25. This assignment 
could be verified analyzing the selective NOE 
experiment on H3 and H6, where we were able to 
observe the signals of H4. 
 
 
Figure 3. Selective 1D NOE experiments on compound A. 
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Figure 4. Selective 1D NOE experiments on compound B. 
The same argument could be applied for the 
structure elucidation of compound B (Figure 4). The 
ortho aromatic protons exhibited NOE enhancement 
with H6, which in turn transferred nuclear spin 
polarization through transverse relaxation with H4. 
This effect was also observed between H4 and the 
proton in alpha position to OTBDPS group. These 
data ratified the assignment of compound B with the 
structure of 26. In this case, the anisotropy effect of 
the aromatic ring made possible to observe the ortho 
protons when H6 was irradiated. 
After successfully complete structure elucidation 
of the isomers 25 and 26, the TBDPS group was 
removed with a saturated solution of HCl in EtOH, 
giving the final compounds 7 and 8, respectively. 
 
Biological Evaluation 
The biological activity of the newly synthesized 
analogues was tested in vitro, and the results are 
summarized in Table 2 and Figures 5-8. 
Table 2. Biological activities of 19-nor analogues of 
1α,25-(OH)2-D3.a) 
Compound VDR 
(%) 
hDBP 
(%) 
MFC-7 
(%) 
HL 60 
(%) 
1α,25-(OH)2-D3 100 100 100 100 
19-nor-1α,25-(OH)2-D3 100 10 116 170 
7 1.2 14 18 10 
8 0.4 3 12 6 
a) Values are expressed as percentages of activity EC50 
concentration relative to 1α,25-(OH)2-D3 (100%). 
The affinity of compounds 7 and 8 for pig mucosa 
cytosol VDR and for human vitamin D binding 
protein (hDBP) was evaluated in comparison to the 
natural hormone and its 19-nor derivative. In addition, 
inhibition of MCF-7 breast cancer and HL60 
leukemia cell proliferation by 1α,25-(OH)2-D3, 1α,25-
(OH)2-19-nor-D3, and analogues 7 and 8 was 
measured. 
 
Figure 5. Affinity of 1α,25-(OH)2-D3 and 19-nor 
analogues for pig vitamin D receptor (VDR). Notes: 1α,25-
(OH)2-D3 (●);1α,25-(OH)2-19-nor-D3 (¢); 7 (q); 8 (☐). 
The 1α,25-(OH)2-19-nor-D3 analogue, possesing 
the same configuration of the natural hormone at C-1 
and C-3 positions, has the same potency in terms of 
its ability to bind to the pig VDR, but analogues 7 
and 8 have markedly reduced affinity for the VDR 
(Table 2 and Figure 5). 
When comparing hDBP binding among the three 
1,25-19-nor analogues, compound 7 exhibited the 
highest affinity, which was still seven times lower 
than that of 1α,25-(OH)2-D3 (Table 2 and Figure 6). 
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Figure 6. Affinity of 1α,25-(OH)2-D3 and 19-nor 
analogues for human vitamin D binding protein (hDBP). 
Notes: 1α,25-(OH)2-D3 (●);1α,25-(OH)2-19-nor-D3 (¢); 7 
(q); 8 (☐). 
As a measure of the antiproliferative activity of 
1,25-19-nor analogues, [3H]thymidine incorporation 
of MCF-7 breast cancer cells and HL 60 leukemia 
cells was measured after a 72 h incubation period 
with various concentrations of 1α,25-(OH)2-D3, 
analogues or ethanol. The most active compound is 
the 1α,25-(OH)2-19-nor-D3, which is slightly more 
active than the natural hormone. Analogues 7 and 8 
showed 6-10 and 8-17 fold lower activities than 
1α,25, respectively, on MCF-7 and HL 60 cells (Table 
1 and Figures 7 and 8). 
 
Figure 7. In vitro antiproliferative effects of 1α,25-(OH)2-
D3 and 19-nor analogues on breast cancer MCF-7 cells. 
Notes: Vehicle (); 1α,25-(OH)2-D3 (●);1α,25-(OH)2-19-
nor-D3 (¢); 7 (q); 8 (☐). 
 
Figure 8. In vitro antiproliferative effects of 1α,25-(OH)2-
D3 and 19-nor analogues on promyelocytic HL 60 
leukemia cells. Notes: Vehicle (); 1α,25-(OH)2-D3 
(●);1α,25-(OH)2-19-nor-D3 (¢); 7 (q); 8 (☐). 
These findings prove the key role of the 
stereochemistry in the biological activity and this 
would be reflected in different pharmacokinetic 
profiles of theses analogues. 
Conclusion 
The synthesis of A-ring diastereomers of 1α,25-
(OH)2-19-nor-D3 has been successfully accomplished. 
For the construction of the diene unit, a strategy 
based on a Julia-Kocienski olefination between the 
sulfone 12 and the cyclohexanone derivative 11 was 
employed. cis,cis-1,3,5-Cyclohexanetriol, a 
commercial available compound with the appropriate 
stereochemistry, was used as starting material for the 
A-ring precursor. To elucidate the structure of the 19-
nor analogues, an alternative synthesis was carried 
out through orthogonally protected derivatives. It is 
noteworthy the importance of the biocatalytic 
desymmetrization process of 15 to give different 
chemical nature to the A-ring hydroxyl groups. This 
step was successfully performed with Pseudomonas 
cepacia lipase as catalyst, vinyl acetate as acylating 
reagent, and toluene or TBME as solvents. The 
preparation of these 19-nor-analogues has not been 
described previously, probably due to the complexity 
in structure elucidation of the diastereoisomers. The 
structure of both compounds was established by 
selective NOE NMR spectroscopy, homonuclear 
(COSY, TOCSY) and heteronuclear (HSQC, HMBC) 
correlations. Biological assays on 1,25-19-nor 
analogues 7 and 8 have shown poor binding to VDR, 
whereas 1α,25-(OH)2-19-nor-D3 has the same affinity 
as the natural hormone. All three 1,25-19-nor 
analogues have a lower affinity for hDBP than 1α,25-
(OH)2-D3. The most active compound in the 
inhibition of MCF-7 cell proliferation and HL 60 cell 
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differentiation was 1α,25-(OH)2-19-nor-D3, even 
slightly higher than 1α,25. 
Experimental Section 
General Considerations. All reagents were at highest 
commercial quality and used without further purification. 
All non-aqueous reactions were carried out under argon 
atmosphere in anhydrous, freshly destilled, solvents. 
Candida antarctica lipase type B (CAL-B, Novozyme 435, 
immobilized by adsorption in Lewatit, 9120 PLU/g) was 
kindly donated by Novozyme. Pseudomonas cepacia 
lipase (Lipase PS “Amano IM”, immobilized on 
diatomaceous earth, 943 U/g) was purchased from Amano 
Enzyme. Reactions were monitored by TLC carried out 
using UV light as visualizing agent and/or spraying a 5% 
aqueous sulphuric acid solution containing cerium(IV) 
sulphate (1%) and molybdophosphoric acid (2.5%). Flash 
chromatography was performed using silica gel 60 (230–
400 mesh). 1H, 13C NMR, and DEPT were obtained using 
300.13, 400.13 or 600.13 MHz apparatus for 1H, and 75.5, 
90.61 or 150.90 MHz for 13C. The same spectrometers 
were used for the acquisition of 1H-1H homonuclear 
(COSY, TOCSY, and NOESY) and 1H-13C heteronuclear 
(HSQC and HMBC) correlations. Optical rotations were 
recorded on a polarimeter, and values are reported as 
follows: [α]λT (c: g/100 mL, solvent). IR spectra were 
recorded as thin films on NaCl plates or KBr pellets on an 
Infrared FT spectrophotometer. Mass spectra (MS) and 
high resolution mass spectra (HRMS) were recorded on a 
mass spectrometer under electron spray ionization (ESI) or 
atmospheric pressure chemical ionization (APCI) 
conditions. 
1a,25-Dihydroxy-3-epi-19-nor-vitamin D3 (7). To a 
solution of 13 (13.86 mg, 0.03 mmol) or 25 (19.29 mg, 
0.03 mmol) in EtOH (622 µL), a saturated solution of HCl 
in EtOH (7.6 mL) was added. The reaction was stirred for 
30 min. Then, the solvent was removed, the mixture was 
extracted with a saturated aqueous solution of NaHCO3 
and Et2O, and the organic extract was washed with brine 
and dried (Na2SO4). The residue was purified by column 
chromatography using 80% EtOAc/hexane as eluent. Rf: 
0.2 (90% EtOAc/hexane); 1H NMR (600.13 MHz, CDCl3): 
δ 0.54 (s, 3H, Me18), 0.84 (m, 1H), 0.93 (d, 3H, Me21, J 6.4 
Hz), 1.21 (s, 6H, Me26 + Me27), 1.25–2.10 (several m), 
2.25 (dd, 1H, H4ax, J 13.2, 7.1 Hz), 2.40 (d, 1H, H10ax, J 
13.1, 7.1 Hz), 2.48 (dd, 1H, H4eq, J 13.7, 3.6 Hz), 2.59 (dd, 
1H, H10eq, J 13.5, 3.5 Hz), 2.81 (dd, 1H, H9eq, J 12.4, 4.0 
Hz), 3.90 (m, 1H, H1 + H3), 5.85 (d, 1H, H7, J 11.2 Hz), 
6.31 (d, 1H, H6, J 11.3 Hz) ppm; 13C NMR (150.5 MHz, 
CDCl3): δ 12.2 (Me18), 19.0 (Me21), 21.0 (CH2), 22.4 (CH2), 
23.6 (CH2), 27.8 (CH2), 29.0 (CH2), 29.3 and 29.5 (Me26 + 
Me27), 36.2 (CH, C20), 36.5 (CH2), 37.0 (CH2), 40.6 (CH, 
C2), 41.4 (CH2), 44.6 (CH2), 45.3 (CH2), 45.9 (C, C13), 
56.5 and 56.7 (2CH, C14 and C17), 68.7 and 69.0 (2CH, C1 
+ C3), 71.3 (C, C25), 115.6 (CH, C7), 124.2 (CH, C6), 130.1, 
and 142.9 (2CH, C5 + C8) ppm; MS (ESI+, m/z): 405 
[(M+H)+, 100%]. 
1β,25-Dihydroxy-19-nor-vitamin D3 (8). For the 
synthesis of this derivative, we employed the same 
procedure as 7 but starting from 14 or 26. Rf: 0.2 (90% 
EtOAc/hexane); 1H NMR (600.13 MHz, CDCl3): δ 0.55 (s, 
3H, Me18), 0.88 (m, 1H), 0.93 (d, 3H, Me21, J 6.5 Hz), 1.21 
(s, 6H, Me26 + Me27), 1.25–2.07 (several m), 2.30 (dd, 1H, 
H4ax, J 13.4, 6.0 Hz), 2.47 (apparent d, 2H, H4eq+ H10eq, J 
13.6 Hz), 2.56 (dd, 1H, H10ax, J 13.7, 6.1 Hz), 2.81(dd, 1H, 
H9eq, J 11.7, 4.1Hz), 4.00 (m, 2H, H1 + H3), 5.86 (d, 1H, H7, 
J 11.2 Hz), 6.34 (d, 1H, H6, J 11.2 Hz) ppm; 13C NMR 
(150.5 MHz, CDCl3): δ 12.2 (Me18), 19.0 (Me21), 21.0 
(CH2), 22.4 (CH2), 23.6 (CH2), 27.8 (CH2), 29.1 (CH2), 
29.4 and 29.5 (Me26 + Me27), 36.3 (CH, C20), 36.5 (CH2), 
36.8 (CH2), 40.4 (CH, C2), 41.0 (CH2), 44.6 (CH2), 44.8 
(CH2), 45.9 (C, C13), 56.4 and 56.6 (2CH, C14 + C17), 68.8 
and 69.0 (2CH, C1 + C3), 71.3 (C, C25), 115.5 (CH, C7), 
124.2 (CH, C6), 130.1 and 142.9 (2CH, C5 + C8) ppm; MS 
(ESI+, m/z): 405 [(M+H)+, 100%]. 
(1r,3R,5S)-3,5-bis(tert-Butyldimethylsilyloxy)cyclo-
hexanol (10). To a solution of 9 (1.0 g, 7.57 mmol) in 
anhydrous THF (30 mL) at −20 ºC, were successively 
added anhydrous Et3N (2.1 mL, 15.14 mmol) and tert-
butyldimethylsilyl chloride (2.3 g, 15.14 mmol). The 
reaction was stirred at this temperature for 2 h and then 
16 h at r.t. The solvent was evaporated and the crude was 
purified by column chromatography (30% Et2O/hexane) to 
give the compound 10 as a white solid in 43% yield; Rf: 
0.4 (30% Et2O/hexane); mp 78-80 °C; IR (KBr): ν 3269, 
2943, 2928, 1471, 1463, 1378 cm-1; 1H NMR (300.13 MHz, 
CDCl3): δ 0.05 (s, 12H, SiMe), 0.87 (s, 18H, SiCMe3), 1.32 
(m, 3H, H2ax + H4ax + H6ax), 1.72 (s, 2H, OH), 1.99 (m, 1H, 
H6eq), 2.11 (m, 2H, H2eq+ H4eq), 3.57 (m, 3H, H1 + H3 + H5) 
ppm; 13C NMR (75.5 MHz, CDCl3): δ −4.6 (SiMe), −4.5 
(SiMe), 18.3 (SiC), 26.0 (CH3, SiCMe3), 44.8 (C2 + C6), 
45.1 (C4), 66.2 (C1), 66.7 (C3 + C5) ppm; MS (APCI+, m/z): 
361 [(M+H)+, 25%], 383 [(M+Na)+, 100%]. 
(3R,5S)-3,5-bis(tert-Butyldimethyllsilyloxy)cyclo-
hexanone (11). To a solution of 10 (295 mg, 0.82 mmol) 
in anhydrous CH2Cl2 (8.2 mL), Dess-Martin reagent was 
added (381 mg, 0.898 mmol). The mixture was stirred at r.t. 
for 30 min. Then, it was diluted with Et2O (9.5 mL) and a 
mixture of saturated aqueous Na2S2O3 and NaHCO3 
solution (1:1, v/v, 9.5 mL), obtaining a white precipitate 
that disappeared after 10 min. The mixture was extracted 
with Et2O. The combined organic fractions were dried 
(Na2SO4), filtered and concentrated. Purification of the 
crude by column chromatography (5% Et2O/hexane) gave 
11 as a white solid in 97% yield; Rf: 0.4 (10% 
Et2O/hexane); mp: 62-64 °C; IR (KBr): ν 2953, 2928, 2856, 
1712, 1471, 1463, 1389 cm-1; 1H NMR (300.13 MHz, 
CDCl3): δ −0.04 (s, 6H, SiMe), 0.04 (s, 6H, SiMe), 0.86 (s, 
18H, SiCMe3), 1.76 (m, 1H, H4ax), 2.25 (m, 1H, H4eq), 2.23 
(dd, 2H, H2ax + H6ax, J 13.7, 11.2 Hz), 2.53 (dd, 2H, J 13.7, 
3.9 Hz, H2eq + H6eq), 3.78 (m, 2H, H3 + H5) ppm; 13C NMR 
(75.5 MHz, CDCl3): δ −4.6 (SiMe), 18.1 (SiC), 25.9 (CH3, 
SiCMe3), 45.2 (C4), 51.0 (C2 + C6), 66.0 (C3 + C5), 207 
(C=O) ppm; MS (ESI+, m/z): 359 [(M+H)+, 5%], 383 
[(M+Na)+, 100%]. 
Procedure for the synthesis of 13 and 14. To a solution 
of 12 (167 mg, 0.30 mmol) in anhydrous THF (1.1 mL) at 
−78 ºC was added dropwise LHMDS (305 μL, 1.0 M in 
THF, 0.30 mmol), resulting in a deep red colour solution. 
The mixture was stirred at the same temperature for 2 h, 
and then, a solution of the corresponding ketone 11 (63 mg, 
0.19 mmol) in anhydrous THF (1.2 mL) was added 
dropwise to the mixture via cannula transfer. After being 
stirred at −50 ºC during 5 h, the reaction mixture was 
poured into a saturated aqueous solution of NH4Cl and 
extracted with Et2O. The combined organic fractions were 
dried (Na2SO4), filtered, and concentrated to give a crude 
that was purified by column chromatography (4% 
Et2O/hexane) to give an equimolecular diastereomeric 
mixture in 51% yield. Then, TBAF (725 µL, 1 M in THF, 
0.70 mmol) was added dropwise to the epimeric mixture 
(100 mg, 0.10 mmol) in anhydrous THF (1.5 mL) at 0 ºC 
in darkness. After 5 min, the mixture was stirred at r.t. for 
2 h. Then, solvent was evaporated and the mixture was 
extracted with EtOAc. The combined organic fractions 
were dried (Na2SO4), concentrated, and the residue 
purified by column chromatography (60% Et2O/hexane). 
The diastereoisomers were isolated by preparative HPLC 
(SunFire® C18 Column, 100 Å, 5  m, 10 mm x 250 mm). 
Conditions: 4.0 mL/min, 10% iPrOH/hexane. 
25-Ethoxymethyloxy-1a-hydroxy-3-epi-19-nor-vitamin 
D3 (13). Rf: 0.2 (60% EtOAc/hexane). IR (NaCl): ν 3367, 
2943, 2872, 1463, 1380 cm-1; 1H NMR (600.13 MHz, 
CDCl3): δ 0.54 (s, 3H, Me18), 0.92 (d, 3H, Me21, J 6.5 Hz), 
1.02 (m, 1H, H22), 1.20 (t, 3H, H3´, J 4.0 Hz), 1.21 (s, 6H, 
Me26 + Me27), 1.28 (m, 4H, H17 + H12 + H16), 1.39 (m, 5H, 
H20 + 1H22 + 1H24 + H23), 1.51 (m, 6H, 2H15 + 1H24 + 3H), 
1.66 (m, 3H, 1H9 + 2H11), 1.78 (m, 1H, H2ax), 1.88 (m, 1H), 
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1.99 (dd, 3H, H12, J 11.4, 8.1 Hz), 2.06 (dt, 1H, H2eq, J 12.9, 
3.3 Hz), 2.24 (dd, 2H, H4ax + OH, 13.2, 7.1 Hz), 2.39 (dd, 
1H, H10ax, 13.5, 7.2 Hz), 2.48 (dd, 1H, H4ax, J 14.0, 3.2 Hz), 
2.48 (dd, 1H, H4eq, J 13.3, 3.6 Hz), 2.59 (dd, 1H, H10eq, J 
13.5, 3.5 Hz), 2.80 (m, 1H, H9), 3.61 (q, 2H, J 7.1 Hz, H2´), 
3.90 (m, 2H, H3 + H1), 4.75 (s, 2H, H1´), 5.85 (d, 1H, H7, J 
11.3 Hz), 6.31 (d, 1H, H6, J 11.2 Hz) ppm; 13C NMR 
(150.5 MHz, CDCl3): δ 12.2 (Me18), 15.3 (Me3´), 18.9 
(Me21), 20.7 (CH2, C23), 22.4 (CH2, C15), 23.6 (CH2, C11), 
26.5 y 26.6 (Me 26 + Me27) 27.8 (CH2, C16), 29.0 (CH2, C9), 
36.3 (CH, C20), 36.6 (CH2, C22), 37.0 (CH2, C10), 40.6 
(CH2, C12), 41.4 (CH2, C2), 42.4 (CH2, C24), 45.3 (CH2, C4), 
45.9 (C, C13), 56.4 (CH, C14), 56.7 (CH, C17), 63.1 (CH2, 
C2´), 68.7 (CH, C3), 68.9 (CH, C1), 76.4 (C, C25), 89.6 
(CH2, C1´), 115.5 (CH, C7), 123.8 (CH, C6), 130.3 (C, C5), 
142.9 (C, C8) ppm; MS (ESI+, m/z): 485 [(M+Na)+, 50%]. 
25-Ethoxymethyloxy-1β-hydroxy-19-nor-vitamin D3 
(14). Rf: 0.2 (60% EtOAc/hexane). IR (NaCl): ν 3368, 
2943, 2872, 1458, 1348 cm-1; 1H NMR (600.13 MHz, 
CDCl3): δ 0.54 (s, 3H, Me18), 0.93 (d, 3H, Me21, J 6.5 Hz), 
1.03 (dd, 1H, H22, J 20.0, 9.7 Hz), 1.20 (t, 3H, H3´, J 4.0 
Hz,), 1.21 (s, 6H, Me26 + Me27), 1.29 (m, 4H, H17 + 2H12 + 
H16), 1.40 (m, 4H, H20 + 1H22 + 1H24 + 1H23), 1.50 (m, 5H, 
H15 + 1H24+ 2H), 1.66 (m, 3H, 1H9 + 2H11), 1.86 (m, 2H, 
1H2 + 1H16), 1.99 (m, 3H, H2 + H14), 2.29 (dd, 1H, H4, J 
13.4, 6.2 Hz), 2.34 (s, 1H, OH), 2.47 (dd, 1H, H10, J 14.0, 
3.2 Hz), 2.48 (dd, 1H, H10, J 12.6, 2.7 Hz), 2.56 (dd, 1H, 
H10, J 13.8, 6.1 Hz), 2.81 (dd, 1H, H9, J 13.6, 5.3 Hz), 3.61 
(q, 2H, J 7.1 Hz, H2´), 4.00 (m, 2H, H3 + H1), 4.75 (s, 2H, 
H1´), 5.86 (d, 1H, H7, J 11.3 Hz), 6.33 (d, 1H, H6, J 11.3 
Hz) ppm; 13C NMR (150.5 MHz, CDCl3): δ 12.2 (Me18), 
15.3 (Me3´), 18.9 (Me21), 20.6 (CH2, C23), 22.4 (CH2, C15), 
23.7 (CH2, C11), 26.5 and 26.6 (Me26 + Me 27) 27.8 (CH2, 
C16), 29.1 (CH2, C9), 36.3 (CH, C20), 36.6 (CH2, C22), 36.8 
(CH2, C10), 40.4 (CH2, C2), 40.6 (CH2, C12), 42.4 (CH2, 
C24), 45.2 (CH2, C4), 45.9 (C, C13), 56.4 (CH, C14), 56.7 
(CH, C17), 63.1 (CH2, C2´). 68.8 (CH, C3), 69.0 (CH, C1), 
76.4 (C, C25), 89.6 (CH2, C1´), 115.5 (CH, C7), 124.2 (CH, 
C6), 130.1 (C, C5), 142.9 (C, C8) ppm; MS (ESI+, m/z): 387 
[(M-OCH2OEt)+, 100%], 399 [(M-2OH-Et)+, 100%], 463 
[(M+H)+, 75%], 485 [(M+Na)+, 50%]. 
 (1R,3S,5s)-5-(tert-Butyldiphenylsilyloxy)cyclohexane-
1,3-diol (15). To a solution of 9 (1 g, 7.18 mmol) in 
anhydrous THF (20 mL) at r.t. were successively added 
TBDPSCl (2.3 mL, 8.62 mmol) and anhydrous Et3N (1.2 
mL, 8.62 mmol). After being stirred at this temperature for 
30 min, NaH was added (60% w/w in mineral oil, 372 mg, 
9.35 mmol). When the solution stopped bubbling, the 
mixture was heated to 45 ºC for 48 h. After this time, it 
was cooled to 0 ºC and filtered over Celite®. Solvents were 
evaporated and the residue purified by column 
chromatography (EtOAc as eluent) to give the diol 15 in 
85% yield. Rf: 0.4 (80% EtOAc/hexane); mp: 94-96 °C; IR 
(KBr): ν 3324, 3052, 2939, 2860, 1961, 1904, 1826, 1475 
cm-1; 1H NMR (300.13 MHz, CDCl3): δ 1.06 (s, 9H, 
SiCMe3), 1.30 (m, 1H, H2ax), 1.44 (dt, 2H, H4ax + H6ax, J 
17.6, 8.8 Hz), 2.09 (m, 3H, H2eq + H4eq +H6eq), 2.24 (s, 2H, 
OH), 3.46 (ddd, 2H, H1 + H3, J 14.3, 10.2, 3.9 Hz), 3.67 (m, 
1H, H5), 7.40 (m, 6H, Hmeta + Hpara), 7.68 (dd, 4H, Hortho, J 
7.7, 1.6 Hz) ppm; 13C NMR (75.5 MHz, CDCl3): δ 19.2 
(SiC), 27.0 (CH3, SiCMe3), 43.4 (CH2, C2), 43.6 (2CH2, C4 
+ C6), 65.9 (2CH, C1 + C3), 67.5 (CH, C5), 127.8 (4CH, 
Cmeta), 129.8 (2CH, Cpara), 134.0 (2C, Cipso), 135.8 (4CH, 
Cortho) ppm; MS (ESI+, m/z): 371 [(M+H)+, 100%]; HRMS 
(ESI+, m/z): calcd for C22H30NaO3Si [(M+Na)+]: 393.1856, 
found: 393.1860. 
(1R,3S,5S)-3-(tert-Butyldiphenylsilyloxy)-5-
hydroxycyclohexyl acetate (16). Enzymatic reactions: A 
mixture of compound 15 (540 mg, 1.46 mmol), lipase (270 
mg) and vinyl acetate (672 μL, 7.29 mmol) in the 
anhydrous solvent (0.2 M, 7.3 mL) was shaken at 30 ºC 
and 250 rpm. The progress of the reaction was analyzed by 
TLC (50% EtOAc/hexane) until the achievement of the 
complete conversion (4-12 h). Then, the enzyme was 
removed by filtration and washed with CH2Cl2. The crude 
residue was purified by column chromatography (20-40% 
EtOAc/hexane as gradient eluent) to give 16 in 99% yield. 
Racemic derivative (for the HPLC analyses): To a solution 
of 15 (100 mg, 0.27 mmol) in anhydrous CH2Cl2 (2.7 mL) 
at 0 ºC, Et3N (63 μL, 0.46 mmol), DMAP (4 mg, 0.033 
mmol) and acetic anhydride (38 μL, 0.40 mmol, dropwise) 
were successively added. The reaction was stirred at r.t. for 
2 h and then the solvent was evaporated and the residue 
purified by column chromatography (20-40% 
EtOAc/hexane as gradient eluent) to give the racemic 
derivative 16 (65% yield). Rf: 0.5 (40% EtOAc/hexane); 
IR (NaCl): ν 3425, 3070, 3048, 2953, 2858, 1961, 1902, 
1825, 1737, 1472, 1427 cm-1; [α]D20= −12 (c 1.0, CHCl3); 
1H NMR (300.13 MHz, CDCl3): δ 1.05 (s, 9H,SiCMe3), 
1.24-1.67 (m, 4H, H2ax + H4ax +H6ax+ OH), 2.01 (s, 3H, Me, 
OAc), 2.10 (m, 3H, H2eq + H4eq + H6eq), 3.50 (m, 1H, H5), 
3.69 (m, 1H, H3), 4.56 (m, 1H, H1), 7.41 (m, 6H, Hmeta + 
Hpara), 7.65 (dd, 4H, Hortho, J 7.7, 1.6 Hz) ppm; 13C NMR 
(75.5 MHz, CDCl3): δ 19.2 (SiC), 21.4 (Me, OAc), 27.0 
(CH3, SiCMe3), 39.9 (CH2), 40.0 (CH2), 43.7 (CH2), 65.6 
(CH, C5), 67.1 (CH, C3), 67.9 (CH, C1), 127.8 (4CH, Cmeta), 
129.9 (2CH, Cpara), 133.9 (C, Cipso), 134.0 (C, Cipso), 135.9 
(4CH, Cortho), 170.5 (C=O) ppm; MS (ESI+, m/z): 413 
[(M+H)+, 100%]; HRMS (ESI+, m/z): calcd for 
C24H32NaO4Si [(M+Na)+]: 435.1962, found: 435.1983. 
(1R,3R,5S)-3-(tert-Butyldiphenylsilyloxy)-5-(tert-
butyldimethylsilyloxy)cyclohexyl acetate (17). To a 
solution of 16 (500 mg, 1.21 mmol) in anhydrous CH2Cl2 
(4.8 mL) at 0 ºC, were added imidazole (215 mg, 
3.15 mmol) and tert-butyldimethylsilyl chloride (439 mg, 
2.91 mmol). Afterwards, the reaction was stirred at r.t. for 
3 h. Then, solvent was evaporated and the residue purified 
by column chromatography (10% Et2O/hexane as eluent) 
to give 17 in 94% yield. Rf: 0.5 (10% EtOAc/hexane); IR 
(NaCl): ν 3425, 3070, 3048, 2953, 2858, 1961, 1902, 1825, 
1737, 1472, 1427 cm-1; [α]D20=  3 (c 1.0, CHCl3); 1H 
NMR (300.13 MHz, CDCl3): δ −0.04 (s, 3H, SiMe), −0.03 
(s, 3H, SiMe), 0.85 (s, 9H, SiCMe3, TBDMS) 1.11 (s, 9H, 
SiCMe3, TBDPS), 1.36 (m, 2H, H2ax + H6ax), 1.51 (dd, 1H, 
H4ax, J 21.8, 10.3 Hz), 1.98 (m, 1H, H4eq), 2.00 (s, 6H, Me, 
OAc), 2.09 (m, 1H, H2eq), 2.22 (m, 1H, H6eq) 3.40 (m, 1H, 
H3), 3.65 (m, 1H, H5), 4.57 (m, 2H, H1), 7.41 (m, 6H, Hmeta 
+ Hpara), 7.65 (dd, 4H, Hortho, J 7.8, 1.6 Hz) ppm; 13C NMR 
(75.5 MHz, CDCl3): δ −4.7 (SiMe), −4.6 (SiMe), 18.1 
(SiC), 19.2 (SiC), 21.3 (Me, OAc), 25.9 (SiCMe3, 
TBDMS), 27.0 (SiCMe3, TBDPS), 40.6 (CH2, C6), 40.9 
(CH2, C2), 45.0 (CH2, C4), 66.1 (CH, C3), 67.2 (CH, C5), 
68.0 (CH, C1), 127.6 (2CH, Cmeta), 127.7 (2CH, Cmeta) 
129.8 (2CH, Cpara), 134.2 (2C, Cipso), 134.4 (2C, Cipso), 
135.8 (2CH, Cortho), 135.9 (2CH, Cortho), 170.2 (C=O) ppm; 
MS (ESI+, m/z): 527 [(M+H)+, 100%]. 
(1R,3R,5S)-3-(tert-Butyldiphenylsilyloxy)-5-(tert-
butyldimethylsilyloxy)cyclohexan-1-ol (18). To a 
solution of 17 (520 mg, 0.99 mmol) in anhydrous MeOH 
(4.8 mL), MeONa (140 mg, 2.47 mmol) was added, 
showing a progressive cloudiness. After being stirred at r.t. 
for 4 h, solid ammonium chloride was added until the 
medium was neutralized. Then, the solvent was evaporated, 
the residue was dissolved in EtOAc and it was filtered to 
remove the salts. The crude was purified by column 
chromatography (20% Et2O/hexane as eluent) to give 18 in 
95% yield; Rf: 0.4 (20% Et2O /hexane); IR (NaCl): ν 3349, 
3071, 3049, 2951, 2857, 1958, 1887, 1822, 1471, 1427  
cm-1; [α]D20= +9 (c 1.0, CHCl3); 1H NMR (300.13 MHz, 
CDCl3): δ −0.05 (s, 6H, SiMe), 0.84 (s, 9H, SiCMe3, 
TBDMS) 1.07 (s, 9H, SiCMe3, TBDPS), 1.27 (m, 1H), 
1.38 (m, 2H), 1.59 (s, 1H, OH), 1.92 (m, 1H), 2.05 (m, 1H), 
2.15 (m, 1H), 3.38 (m, 2H, H1 + H5), 3.58 (m, 1H, H3), 
7.41 (m, 6H, Hmeta + Hpara), 7.69 (ddd, 4H, Hortho, J 7.9, 4.5, 
1.7 Hz) ppm; 13C NMR (75.5 MHz, CDCl3): δ −4.7 (SiMe), 
−4.6 (SiMe), 18.3 (SiC), 19.2 (SiC), 26.0 (SiCMe3, 
TBDMS), 27.1 (SiCMe3, TBDPS), 44.5 (CH2), 44.7 (CH2), 
44.8 (CH2), 66.1 and 66.4 (2CH, C1 + C5), 67.3 (CH, C3), 
127.7 (4CH, Cmeta), 129.76 (CH, Cpara), 129.81 (CH, Cpara), 
134.31 (C, Cipso), 134.35 (C, Cipso), 135.86 (2CH, Cortho), 
135.88 (2CH, Cortho) ppm; MS (ESI+, m/z): 485 [(M+H)+, 
100%]. 
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(3S,5R)-3-(tert-Butyldiphenylsilyloxy)-5-(tert-
butyldimethylsilyloxy)cyclohexanone (19). To a solution 
of 18 (452 mg, 0.93 mmol) in anhydrous CH2Cl2 (9.0 mL), 
Dess-Martin reagent was added (448 mg, 1.02 mmol). The 
mixture was stirred at r.t. for 1 h and then, it was diluted 
with Et2O (9.5 mL) and a mixture of saturated aqueous 
Na2S2O3 and NaHCO3 solution (1:1, v/v, 9.5 mL), 
obtaining a white precipitate that disappeared after 10 min. 
After that, the mixture was extracted with Et2O. The 
combined organic fractions were dried (Na2SO4), filtered 
and concentrated. Purification of the crude by column 
chromatography (10% Et2O/hexane) gave 19 in 97% yield; 
Rf: 0.7 (20% Et2O/hexane); IR (KBr): ν 3064, 3049, 2951, 
2890, 1958, 1894, 1822, 1717, 1467, 1427 cm-1; [α]D20= 
−1 (c 1.0, CHCl3); 1H NMR (300.13 MHz, CDCl3): δ 
−0.03 (s, 6H, SiMe), 0.86 (s, 9H, SiCMe3, TBDMS) 1.11 (s, 
9H, SiCMe3, TBDPS), 1.84 (m, 1H, H4ax), 2.17 (m, 1H, 
H4eq), 2.35 (dd, 1H, H6ax, J 13.8, 11.1 Hz), 2.50 (dt, 2H, 
H2ax + H6eq, J 14.0, 7.0 Hz), 2.63 (dd, 1H, H2eq, J 14.1, 5.1 
Hz), 3.59 (m, 1H, H5), 3.84 (m, 1H, H3), 7.42 (m, 6H, Hmeta 
+ Hpara) and 7.70 (ddd, 4H, Hortho, J 16.8, 7.6, 1.5 Hz) ppm; 
13C NMR (75.5 MHz, CDCl3): δ −4.9 (SiMe), −4.8 (SiMe), 
18.1 (CSi), 19.1 (SiC), 25.8 (SiCMe3, TBDMS), 27.0 
(SiCMe3, TBDPS), 44.7 (CH2, C4), 50.6 (CH2, C2), 50.9 
(CH2, C6), 65.6 (CH, C5), 66,6 (CH, C3), 127.8 (4CH, 
Cmeta), 130.0 (2CH, Cpara),133.5 (C, Cipso), 133.8 (C, Cipso), 
135.7 (2CH, Cortho), 135.8 (2CH, Cortho), 207.1 (C=O) ppm; 
MS (ESI+, m/z): 483 [(M+H)+, 100%]. 
(1R,3S,5s)-5-(tert-Butyldiphenylsilyloxy)cyclohexan-1,3-
diyl diacetate (20). By-product of the enzymatic reaction. 
Rf: 0.8 (40% EtOAc/hexane); IR (NaCl): ν 3071, 3049, 
2954, 2930, 2857, 1959, 1887, 1738, 1471, 1427 cm-1; 1H 
NMR (300.13 MHz, CDCl3): δ 1.05 (s, 9H, SiCMe3), 1.34 
(q, 1H, H2ax, J 11.6 Hz), 1.48 (c, 2H, H4ax + H6ax, J 11.7 
Hz), 2.00 (s, 6H, Me, OAc), 2.19 (m, 3H, H2eq + H4eq 
+H6eq), 3.67 (m, 1H, H5), 4.53 (m, 2H, H1 + H3), 7.41 (m, 
6H, Hmeta + Hpara), 7.65 (dd, 4H, Hortho, J 7.8, 1.6 Hz) ppm; 
13C NMR (75.5 MHz, CDCl3): δ 19.2 (SiC), 21.2 (Me, 
OAc), 27.0 (CH3, Me2CSi), 36.5 (CH2, C2), 40.5 (CH2, C4 
+ C6), 66.7 (CH, C5), 67.3 (CH, C1 + C3), 127.8 (4CH, 
Cmeta), 129.9 (2CH, Cpara), 133.8 (2C, Cipso), 135.8 (4CH, 
Cortho), 170.1 (C=O) ppm; MS (ESI+, m/z): 455 [(M+H)+, 
100%]. 
(1R,3R)-5-(tert-Butyldiphenylsilyloxy)cyclohexan-1,3-
diyl diacetate (21). To a solution of (−)-16 (60 mg, 
0.15 mmol) in anhydrous THF (250 μL), were successively 
added PPh3 (57 mg, 0.22 mmol), DIAD (42 μL, 0.22 mmol, 
dropwise) and acetic acid (13 μL, 0.22 mmol, dropwise). 
After being stirred at r.t. for 4 h, the solvent was 
evaporated, and the residue purified by column 
chromatography (20% Et2O/hexane) to give the diacetate 
21 (72%). Rf: 0.2 (20% Et2O/hexane); IR (NaCl): ν 3071, 
3049, 2958, 2857, 1961, 1892, 1741, 1734, 1471, 1427  
cm-1; [α]D20= +1 (c 1.0, CHCl3); 1H NMR (300.13 MHz, 
CDCl3): δ 1.05 (s, 9H, SiCMe3), 1.50 (m, 3H, H2ax + H4ax + 
H6ax), 1.80 (s, 3H, Me, OAc). 1.86 (m, 1H, H6eq), 1.96 (m, 
1H, H2eq), 2.02 (s, 3H, MeC=O), 2.26 (m, 1H, H4eq), 3.90 
(m, 1H, H5), 4.88 (m, 1H, H3), 5.14 (m, 1H, H1) 7.39 (m, 
6H, Hmeta + Hpara), 7.70 (dd, 4H, Hortho, J 7.7, 1.6 Hz) ppm; 
13C NMR (75.5 MHz, CDCl3): δ 19.2 (SiC), 21.2 (Me, 
OAc), 21.4 (Me, OAc), 27.0 (SiCMe3), 34.9 (CH2, C2), 
38.6 (CH2, C6), 40.5 (CH2, C4), 66.4 (CH, C5), 68.0 (CH, 
C3), 68.7 (CH, C1), 127.7 (2CH, Cmeta), 127.8 (2CH, Cmeta), 
129.82 (CH, Cpara), 129.83 (CH, Cpara), 134.0 (C, Cipso), 
134.1 (C, Cipso), 135.8 (2CH, Cortho),135.9 (2CH, Cortho), 
170.0 (C=O), 170.4 (C=O) ppm; MS (ESI+, m/z): 455 
[(M+H)+, 100%]. 
(1S,3S)-5-Hydroxycyclohexan-1,3-diyl diacetate (22). 
TBAF (219 µL, 0.22 mmol, 1.0 M in THF) was added 
dropwise to a solution of silyl ether 21 (40 mg, 0.09 mmol) 
in anhydrous THF (437 µL) at 0 ºC in darkness. The 
reaction was stirred at r.t. until TLC (60% Et2O/hexane) 
shows complete consumption of starting material (3 h). 
Then, solvent was evaporated and the mixture was 
extracted with EtOAc. The combined organic fractions 
were dried (Na2SO4) and concentrated under vacuum. The 
crude was purified by column chromatography (30% 
EtOAc/hexane) to give 22 in 79% yield. Rf: 0.3 (30% 
AcOEt/hexane); IR (NaCl): ν 3444, 2958, 2865, 1738, 
1734, 1716, 1435, 1372, 1256, 1238 cm-1; [α]D20= +13.8 (c 
1.0, CHCl3); 1H NMR (300.13 MHz, CDCl3): δ 1.53 (m, 
3H, H2ax + H4ax + H6ax), 1.96 (s, 1H, OH), 2.05 (s, 3H, Me, 
OAc), 2.06 (s, 3H, Me, OAc), 2.08 (m, 2H), 2.28 (m, 1H), 
4.03 (m, 1H, H5), 5.05 and 5.28 (2m, 2H, H1 + H3) ppm; 
13C NMR (75.5 MHz, CDCl3): δ 21.3 (Me, OAc), 21.4 (Me, 
OAc), 34.9 (CH2), 38.3 (CH2), 40.0 (CH2), 65.2 (CH, C5), 
68.2 and 68.5 (2CH, C3 + C1), 170.3 (C=O), 170.4 (C=O) 
ppm; MS (ESI+, m/z): 217 [(M+H)+, 100%]. 
Procedure for the synthesis of 25 and 26. To a solution 
of 12 (300 mg, 0.55 mmol) in anhydrous THF (1.8 mL) at 
−78 ºC was added dropwise LHMDS (520 μL, 1.0 M in 
THF, 0.52 mmol), resulting in a deep red color solution. 
The mixture was stirred at the same temperature for 2 h 
and then, a solution of the corresponding ketone 19 (264 
mg, 0.55 mmol) in anhydrous THF (1.2 mL) was added 
dropwise via cannula transfer. After being stirred at −50 ºC 
during 5 h, the reaction was poured into a saturated 
aqueous solution of NH4Cl and extracted with Et2O. The 
combined organic fractions were dried (Na2SO4), filtered, 
and concentrated to give a crude that was purified by 
column chromatography (4% Et2O/hexane). Then, the 
resulting mixture (269 mg, 0.33 mmol) was dissolved in 
anhydrous CH2Cl2 (3.3 mL), Bi(OTf)3 (238 mg, 0.36 
mmol) was added and the mixture was stirred at 0 ºC for 
2 h. The reaction was quenched by adding a saturated 
aqueous solution of NaHCO3. Next, it was diluted with 
CH2Cl2 and filtered over Celite®. Solvents were evaporated 
under vacuum and the residue purified by column 
chromatography (50% Et2O/hexane). The diastereoisomers 
were isolated by preparative HPLC (SunFire® C18 Column, 
100 Å, 5  m, 10 mm x 250 mm). Conditions: 5.0 mL/min, 
5% iPrOH/hexane. 
1a-(tert-Butyldiphenylsilyloxy)-25-hydroxy-3-epi-19-
nor-vitamin D3 (25). Rf: 0.4 (70% Et2O/hexane); 1H NMR 
(600.13 MHz, CDCl3): δ 0.51 (s, 3H, Me18), 0.88 (m, 1H), 
0.94 (d, 3H, Me21, J 6.4 Hz), 1.06 (s, 9H, SiCMe3), 1.23 (s, 
6H, Me26 + Me27), 1.25–2.07 (several m, 19H), 2.19 (d, 1H, 
H10eq, J 13.8 Hz), 2.37 (dd, 2H, H4, J 10.2, 4.4 Hz), 2.47 
(dd, 1H, H10ax, J 13.7, 5.7 Hz), 2.82 (m, 1H, H9), 3.16 (d, 
1H, J 8.6 Hz), 3.85 (br s, 1H, H3), 4.08 (br s, 1H, H1), 5.73 
(d, 1H, H7, J 11.2 Hz), 6.33 (d, 1H, H6, J 11.3 Hz), 7.38 (q, 
4H, Hmeta, J 7.1 Hz), 7.43 (m, 2H, Hpara), 7.67 (d, 2H, J 6.6 
Hz, ), 7.71 (d, 2H, J 7.71 Hz) ppm; 13C NMR (150.5 MHz, 
CDCl3): δ 12.3 (Me18), 18.9 (Me21), 19.4 (CSi), 21.0 (CH2), 
22.5 (CH2), 23.6 (CH2), 27.2 (SiCMe3), 27.8 (CH2), 29.0 
(CH2) 29.3 y 29.5 (Me26 + Me27), 36.3 (CH, C20), 36.5 
(CH2), 36.6 (CH2), 40.7 (CH2, C2), 40.5 (CH2), 44.6 (CH2), 
45.5 (CH2), 45.9 (C, C13), 56.4 and 56.7 (2CH, C14 + C17), 
68.9 (CH, C3), 70.6 (CH, C1), 71.5 (C, C25), 115.8 (CH, C7), 
124.0 (CH, C6), 127.75 and 127.83 (2CH, Cmeta), 129.90 
and 130.02 (2CH, Cpara), 130.6 (C5), 133.4 and 133.7 (2C, 
Cipso) 135.97 and 136.06 (2CH, Cortho), 142.3 (C8) ppm. 
3-(tert-Butyldiphenylsilyl)-1β,25-dihydroxy-19-nor-
vitamin D3 (26). Rf: 0.4 (70% Et2O/hexane); 1H NMR 
(600.13 MHz, CDCl3): δ 0.53 (s, 3H, Me18), 0.88 (m, 1H), 
0.94 (d, 3H, Me21, J 6.4 Hz), 1.05 (s, 9H, SiCMe3), 1.22 (s, 
6H, Me26 + Me27), 1.25–2.07 (several m, 20 H), 2.18 (m, 
1H, H4eq), 2.40 (dd, 1H, H10eq, J 13.4, 3.3 Hz), 2.54 (dd, 1H, 
H10ax, J 13.5, 6.3 Hz), 2.78 (dd, 1H, H9eq, J 14.2, 4.4 Hz), 
2.94 (d, 1H, H2eq, J 9.1 Hz), 3.84 (br s, 1H, H1), 3.99 (m, 
1H, H3), 5.14 (br s, 1H, OH), 5.86 (d, 1H, H7, J 11.2 Hz), 
6.16 (d, 1H, H6, J 11.2 Hz), 7.38 (m, 4H, Hmeta), 7.43 (m, 
2H, Hpara), 7.67 (d, 2H, J 7.9 Hz, ), 7.70 (d, 2H, J 6.7 Hz) 
ppm; 13C NMR (150.5 MHz, CDCl3): δ 12.2 (Me18), 18.9 
(Me21), 19.2 (CSi), 21.0 (CH2), 22.4 (CH2), 23.6 (CH2), 
27.2 (SiCMe3), 27.9 (CH2), 29.0 (CH2), 29.4 and 29.5 
(Me26 + Me27), 36.3 (CH, C20), 36.6 (CH2), 37.1 (CH2), 40.4 
(CH2), 40.6 (CH2), 44.5 (CH2), 45.2 (CH2), 45.9 (C, C13), 
56.4 and 56.6 (2CH, C14 + C17), 68.7 (CH, C3), 71.0 (CH, 
C1), 71.3 (C, C25), 115.9 (CH, C7), 124.2 (CH, C6), 127.78 
and 127.81 (2CH, Cmeta), 129.90 and 129.95 (2CH, Cpara), 
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130.5 (C5), 133.7 and 134.0 (2C, Cipso) 136.00 and 136.09 
(2CH, Cortho), 142.3 (C8) ppm. 
In vitro Biological Evaluation 
Affinity for VDR. The affinity of 1α,25-(OH)2-D3 and its 
analogues to the vitamin D receptor was evaluated by their 
ability to compete with [3H]1α,25-(OH)2-D3 for binding to 
high speed supernatant from intestinal mucosa 
homogenates obtained from normal pigs as described 
previously.[12] The relative affinity of the analogues was 
calculated from their concentration needed to displace 50% 
of [3H]1α,25-(OH)2-D3 from its receptor compared with 
the activity of 1α,25-(OH)2-D3 (assigned a 100% value). 
Affinity for DBP. Binding of vitamin D metabolites and 
analogues to hDBP was performed at 4 °C as described 
previously.[13] [3H]1α,25-(OH)2-D3 and 1α,25-(OH)2-D3 or 
its analogues were incubated with hDBP (0.18 μM) in a 
final volume of 1 ml (0.01 M Tris-HCl buffer and 0.154 M 
NaCl, pH 7.4) for 3 h at 4 °C. Phase separation was then 
obtained by the addition of 0.5 ml of cold dextran-coated 
charcoal. 
Cell proliferation assays. As a measure of cell 
proliferation, [3H]-thymidine incorporation of breast 
cancer MCF-7 cells (ATCC) was determined after a 72 h 
incubation period with various concentrations of 1α,25-
(OH)2-D3, analogues or vehicle as described previously.[12] 
Cell differentiation assays. Differentiation of 
promyeolocytic HL-60 leukemia cells (ATCC) was 
measured by the nitro blue tetrazolium (NBT) reduction 
assay after a 72 h incubation period in the presence of 
1α,25-(OH)2-D3, analogues or vehicle.[12] 
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